N-(环丙基甲基)环丙烷甲酰胺 | 26389-63-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-(环丙基甲基)环丙烷甲酰胺
• 英文名称: cyclopropanecarboxylic acid cyclopropylmethyl-amide
• 英文别名: N-cyclopropylmethylcyclopropanecarboxamide；N-(Cyclopropylmethyl)cyclopropanecarboxamide
• CAS: 26389-63-9
• 化学式: C₈H₁₃NO
• 分子量: 139.197
• InChiKey: CNOCZEWICNKWKU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-(环丙基甲基)环丙烷甲酰胺 在 盐酸 、 硼烷 、 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 为溶剂， 反应 22.0h， 生成 potassium 3,5-dinitro-4-(N,N-di(cyclopropylmethyl)amino)benzenesulfonate
  参考文献：
  名称：

  Antikinetoplastid antimitotic activity and metabolic stability of dinitroaniline sulfonamides and benzamides

  摘要：

  N-1-Phenyl-3,5-dinitro-N-4,N-4-di-n-propylsulfanilamide (1) and N-1-phenyl-3,5-dinitro-N-4,N-4-di-n-butylsulfanilamide (2) show potent in vitro antimitotic activity against kinetoplastid parasites but display poor in vivo activity. Seventeen new dinitroaniline sulfonamide and eleven new benzamide analogs of these leads are reported here. Nine of the sulfonamides display in vitro IC50 values under 500 nM against African trypanosomes, and the most active antikinetoplastid compounds also inhibit the in vitro assembly of purified leishmanial tubulin with potencies similar to that of 2. While several of the potent compounds are rapidly degraded by rat liver S9 fractions in vitro, N-1-(3-hydroxy)phenyl-3,5-dinitro-N-4,N-4-di-n-butylsulfanilamide (21) displays an IC50 value of 260 nM against African trypanosomes in vitro and is more stable than 2 in the in vitro metabolism assay. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.04.017
• 作为产物：
  描述：

  环丙基甲胺 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 1-羟基苯并三唑 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.17h， 以87%的产率得到N-(环丙基甲基)环丙烷甲酰胺
  参考文献：
  名称：

  WO2006/73973

  摘要：

  公开号：

文献信息

• Substituted piperidines and methods of use
  申请人：——

  公开号：US20040006067A1

  公开（公告）日：2004-01-08

  Selected substituted piperidine compounds are effective for prophylaxis and treatment of diseases, such as obesity and the like. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving activation of the melanocortin receptor. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  选定的替代哌啶化合物对预防和治疗疾病，如肥胖等，具有有效性。该发明涵盖了新颖化合物、类似物、前药和其药用可接受盐，以及用于预防和治疗涉及黑素皮质素受体激活的疾病和其他疾病或病症的药物组合物和方法。该发明还涉及制备此类化合物的方法，以及在此类方法中有用的中间体。
• Substituted piperazines and methods of use
  申请人：——

  公开号：US20030220324A1

  公开（公告）日：2003-11-27

  Selected substituted piperazine compounds are effective for prophylaxis and treatment of diseases, such as obesity and the like. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving activation of the melanocortin receptor. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  选择的替代哌嗪化合物对于预防和治疗疾病，如肥胖等，具有有效性。该发明涵盖了新型化合物、类似物、前药和其药用盐，以及用于预防和治疗涉及黑素皮质素受体激活的疾病和其他疾病或病症的药物组合物和方法。该发明还涉及制备这类化合物的方法，以及在这些过程中有用的中间体。
• [EN] SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR<br/>[FR] PIPERAZINES SUBSTITUEES COMME MODULATEURS DU RECEPTEUR DE MELANOCORTINE
  申请人：AMGEN INC

  公开号：WO2003009850A1

  公开（公告）日：2003-02-06

  Selected substituted piperazine compounds are effective for prophylaxis and treatment of diseases, such as obesity and the like. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving activation of the melanocortin receptor. The subject invention also relates to processes For making such compounds as well as to intermediates useful in such processes.

  选定的取代哌嗪化合物可用于预防和治疗疾病，如肥胖症等。该发明涵盖了新化合物、类似物、前药及其药学上可接受的盐、制药组合物以及用于预防和治疗涉及黑色素皮质素受体激活的疾病和其他疾病或病症的方法。该发明还涉及制造这些化合物的过程，以及在此类过程中有用的中间体。
• Novel benzylamine derivatives as CETP inhibitors
  申请人：Baruah Anima

  公开号：US20060178514A1

  公开（公告）日：2006-08-10

  The present invention provides, among other things, new benzylamine compounds, compositions comprising benzylamine compounds, methods of making benzylamine compounds, and methods of using benzylamine compounds for treating or preventing a variety of conditions or diseases associated with lipoprotein metabolism.

  本发明提供了包括新的苄胺化合物、含有苄胺化合物的组合物、制备苄胺化合物的方法以及使用苄胺化合物治疗或预防与脂蛋白代谢相关的多种疾病或症状的方法等。
• OXINDOLE DERIVATIVE AS FEEDING CONTROL AGENT
  申请人：Tokunaga Teruhisa

  公开号：US20090131398A1

  公开（公告）日：2009-05-21

  Disclosed is a compound represented by the formula (1) below, a prodrug thereof or a pharmaceutically acceptable salt of either, which is useful as a therapeutic, preventive or ameliorating agent for diabetes and the like. (In the formula, R 3 represents an optionally substituted carbamoyl group or the like; X represents a hydroxyl group or the like; W 1 and W 2 independently represent a single bond or methylene; R 7 and R 8 independently represent a hydrogen atom, an optionally substituted alkyl group or the like; and Ar represents an optionally substituted aryl group or the like.)

  本发明揭示了一种化合物，其化学式表示为(1)，或其前药或药学上可接受的盐，用作治疗、预防或改善糖尿病等疾病的治疗剂、预防剂或改善剂。（其中，R3代表可选取代的氨基甲酰基或类似基团；X代表羟基或类似基团；W1和W2独立地代表单键或亚甲基；R7和R8独立地代表氢原子、可选取代的烷基或类似基团；Ar代表可选取代的芳基或类似基团。）